Authors
Latest:
Dr. de Wit on the AEs With Cabazitaxel in the CARD Trial in mCRPCRonald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the adverse events (AEs) with cabazitaxel (Jevtana) in the phase III CARD trial in patients with metastatic castration-resistant prostate cancer (mCRPC).
Latest:
Dr. Go on Treatment of Patients With Thrombotic MicroangiopathyRonald Go, MD, associate professor of Medicine, Mayo Clinic, discusses treatment for patients with thrombotic microangiopathy.
Latest:
Dr. Hoffman on the Design of an Ongoing Trial Testing PTG-300 in Polycythemia VeraRonald Hoffman, MD, discusses the design of an ongoing phase 2 trial evaluating the first-in-class synthetic hepcidin mimetic PTG-300 in patients with polycythemia vera.
Latest:
Dr. Natale on the Evolution of Immunotherapy in NSCLCRonald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.
Latest:
New Perioperative Strategies Emerge for High-Risk, Resectable RCCThe current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.
Latest:
The Future for HER2-Directed ADCsRonan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.
Latest:
Bringing Epigenetic Therapies From Bench to BedsideEpigenetic therapy has emerged as a novel approach, not necessarily by killing cancer cells, but perhaps by altering the network of chemical changes that affect the DNA/chromatin within cancer cells.
Latest:
Dr. Swords on Anti-Tumor Effects of IMG-98 in AMLRonan T. Swords, MD, discusses preclinical findings demonstrating that the small-molecule inhibitor IMG-98 effectively augments pro-differentiation effects of all-trans-retinoic acid–based therapies in acute myeloid leukemia.
Latest:
Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.
Latest:
Dr. McCulloch on the Likelihood of Relapse on a BTK Inhibitor in MCLRory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the likelihood of relapse on a BTK inhibitor in mantle cell lymphoma (MCL).
Latest:
Dr. Juergens on the IND.226 Trial in Advanced Non-Squamous NSCLCRosalyn Juergens, MD, PhD, assistant professor, Department of Oncology, Division of Medical Oncology, McMaster University, discusses the results of the IND.226 trial, in an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.
Latest:
Dr. Kaplan on the Treatment of Pediatric Patients With SarcomaRosandra N. Kaplan, MD, investigator, Pediatric Oncology Branch, Head, Tumor Microenvironment Section, National Cancer Institute, discusses the treatment of pediatric patients with sarcoma.
Latest:
Dr. Campelo on the Rationale for the ALTA-1L TrialRosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, talks about a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer patients who were treated with brigatinib versus crizotinib.
Latest:
Dr. Lai on Risk Factors Associated With GliomaRose K. Lai, MD, clinical associate professor of Neurology, University of Southern California, discusses results of the Glioma International Case Control study.
Latest:
Lessons on Patient Care Learned at HomeThis fellow shares the insights he’s gained from his wife, a pediatric oncology nurse, and how they help in the care he provides.
Latest:
Dr. Chlebowski on How Weight Loss Improves TNBC SurvivalAs few as five pounds of weight loss can make a significant difference for patients with triple-negative breast cancer, says Rowan Chlebowski, MD, PhD, a medical oncologist at the Los Angeles Biomedical Research Institute at the Harbor-UCLA Medical Center.
Latest:
Breast Cancer Chemoprevention: Targeting the Estrogen ReceptorNew strategies to increase the uptake of these proven breast cancer risk-reduction interventions in general clinical practice are needed.
Latest:
Venous Thromboembolism and Cancer: An Opportunity for Pharmacists to Optimize CareThe management of venous thromboembolism (VTE) disorders is well described in the literature, and comprehensive guidelines are available from the American College of Chest Physicians.
Latest:
Clinics Strive to Improve Revenue and Patient Care Amid a Growing "Cost Consciousness"Growing awareness is prompting a revolution in vigilance and attention to detail that has significance both for the quality of care and financial health of practices.
Latest:
Understanding the Implications of Mandatory Vendor Imposition in OncologyThe rising costs of healthcare have caused payers to analyze spending and take measures to contain costs.
Latest:
Dr. Decker on Pembrolizumab With Concurrent Chemoradiotherapy in Inoperable Locally Advanced NSCLCRoy H. Decker, MD, PhD, discusses the use of pembrolizumab with concurrent chemoradiotherapy in patients with inoperable, locally advanced non–small cell lung cancer.
Latest:
Dr. Herbst on Considerations for Frontline Immunotherapy in NSCLCRoy S. Herbst, MD, PhD, discusses considerations for frontline immunotherapy in non–small cell lung cancer.
Latest:
Blood-Based Biomarkers in NSCLCThe potential clinical utility of blood-based biomarkers in non–small cell lung cancer based on recent data presented at ASCO 2021.
Latest:
Dr Herbst on the Evolution of EGFR Inhibition in Lung CancerRoy S. Herbst, MD, PhD, discusses advances in EGFR inhibition throughout the past several decades in patients with lung cancer.
